Download - ANTEPARTUM CARE

Transcript
Page 1: ANTEPARTUM CARE

ANTEPARTUM CARE

Page 2: ANTEPARTUM CARE

Pregnant Women Who Are ARV Naive (1)

Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic evaluation. Including hepatitis C and tuberculosis screening

All HIV-infected pregnant women should receive a potent combination ARV regimen to reduce the risk of perinatal transmission. (AI) Reducing HIV RNA to undetectable levels lowers the

risk of perinatal transmission, lessens the need for elective C-section to reduce risk of HIV transmission, and reduces risk of ARV drug resistance in the mother.

August 20122 www.aidsetc.org

Page 3: ANTEPARTUM CARE

Pregnant Women Who Are ARV Naive (2)

The choice of regimen should take into account current adult treatment guidelines, what is known about the use of the drugs during pregnancy, and the risk of teratogenicity. (see Guidelines Table 5) Use a dual-NRTI backbone; 1 or more NRTIs should

have high levels of transplacental passage: (AIII) ZDV, 3TC, FTC, TFV, ABC

NVP can be used as a component of the regimen in pregnant women with CD4 counts <250 cells/µL. But NVP should only be used if the benefit clearly outweighs the risk of hepatic toxicity. (AII)

August 20123 www.aidsetc.org

Page 4: ANTEPARTUM CARE

Pregnant Women Who Are ARV Naive (3)

The decision as to whether to start the regimen in the 1st trimester vs delay until 12 weeks’ gestation will depend on CD4 count, VL, and maternal conditions such as nausea and vomiting. (AIII) Earlier initiation may be more effective in reducing risk

of transmission, but benefits must be weighed against potential fetal effects. Fetuses are most susceptible to potential teratogenic effects

in the 1st trimester. Although most transmission occurs late in pregnancy or

during delivery, recent analyses suggest that early control of viral replication may be important.

August 20124 www.aidsetc.org

Page 5: ANTEPARTUM CARE

Pregnant Women Who Are ARV Naive (4)

Conduct drug resistance testing before starting ARVs. However, if HIV is diagnosed or the woman presents

later in pregnancy, start the ARV regimen promptly and adjust, as needed, after resistance testing results are available.

August 20125 www.aidsetc.org

Page 6: ANTEPARTUM CARE

Pregnant Women Who Are ARV Naive (5)

RAL has been suggested for women with a high viral load late in pregnancy because of its ability to rapidly suppress VL. But the safety and efficacy of RAL in this setting have not been evaluated.

Use of ZDV alone for prophylaxis is not optimal, but could be an option, combined with C-section delivery, for women with VL below <1,000 copies/mL who wish to reduce fetal exposure to ARVs.

August 20126 www.aidsetc.org

Page 7: ANTEPARTUM CARE

Pregnant Women Who Are ARV Naive (6)

The regimen initiated during pregnancy can be modified after delivery to a simplified regimen with ARVs that are not used in pregnancy because of insufficient pregnancy safety data. Drugs may be stopped after delivery in women who do

not feel prepared to continue lifelong treatment. Consult with the HIV care provider.

August 20127 www.aidsetc.org

Page 8: ANTEPARTUM CARE

HIV-Infected Pregnant Women Who Are Currently Receiving Antiretroviral Therapy (1)

HIV-infected women who present for care in the 1st trimester should continue any effective ARV regimen. (AII) Including:

Effective EFV-based regimens (CIII) Effective NVP-based regimens (AIII)

Resistance testing should be performed on women with detectable viremia. (AI) >500-1,000 copies/mL

August 20128 www.aidsetc.org

Page 9: ANTEPARTUM CARE

HIV-Infected Pregnant Women Who Are Currently Receiving Antiretroviral Therapy (2)

Rationale for continuing EFV during pregnancy: 1st trimester exposure is not associated with a large

increase in the risk of neural tube defects. The risk of neural tube defects is limited to the first 5-6

weeks of pregnancy, before most pregnancies are recognized.

Treatment changes during pregnancy increase the risk of incomplete viral suppression at the end of pregnancy.

August 20129 www.aidsetc.org

Page 10: ANTEPARTUM CARE

Pregnant Women Who Are ARV-Experienced (1)

Pregnant women with HIV infection who have received ARVs previously for prevention of perinatal transmission: Rates of resistance appear to be low after prophylaxis

with combination ART. But interpretation of resistance testing after treatment discontinuation is complex; resistance testing is most accurate if done while on ARVs or within 4 weeks of discontinuing ARVs.

Treatment failure has not been demonstrated with reinitiation of ART following prophylactic use in pregnancy.

August 201210 www.aidsetc.org

Page 11: ANTEPARTUM CARE

Pregnant Women Who Are ARV-Experienced (2)

Pregnant women with HIV infection who have received ARVs previously for their own health: Choice of ARV regimen is challenging and will vary

by: History of ART Indication for stopping treatment Efficacy of previous ART Results of past and current resistance testing Testing for HLA-B*5701

August 201211 www.aidsetc.org

Page 12: ANTEPARTUM CARE

Pregnant Women Who Are ARV-Experienced (3)

Recommendations:Obtain an accurate history of all prior ARV regimens used for treatment or prevention, including efficacy, tolerance, prior resistance testing, and adherence. (AIII)

Perform drug-resistance testing. (AIII) Initiate therapy or prophylaxis promptly (without

waiting for test results) in women who present late in pregnancy. (BIII)

August 201212 www.aidsetc.org

Page 13: ANTEPARTUM CARE

Pregnant Women Who Are ARV-Experienced (4)

Consult specialists about the choice of regimen in women who previously received ART for their own health. (AIII)

Choose a combination ARV regimen based on results of resistance testing and prior history of ART. (AII) Avoid drugs with teratogenic potential or known

adverse potential for the mother. (AII)

August 201213 www.aidsetc.org

Page 14: ANTEPARTUM CARE

Maternal and Fetal Monitoring during Maternal and Fetal Monitoring during Pregnancy Pregnancy (1)(1)

More frequent VL monitoring during pregnancy is recommended to identify women in whom the decline in VL is slower than expected. Viral suppression generally achieved in 16-24 weeks

in ARV-naive adherent individuals; rare cases take longer.

August 201214 www.aidsetc.org

Page 15: ANTEPARTUM CARE

Maternal and Fetal Monitoring during Maternal and Fetal Monitoring during Pregnancy Pregnancy (2)(2)

Monitor VL: At the initial visit (AI) 2-4 weeks after initiating or changing ARV regimen

(BI) Monthly until VL is undetectable (BIII) At least every 3 months during pregnancy (BIII) At 34-36 weeks’ gestation to inform decisions about

mode of delivery (AIII)

August 201215 www.aidsetc.org

Page 16: ANTEPARTUM CARE

Maternal and Fetal Monitoring during Maternal and Fetal Monitoring during Pregnancy Pregnancy (3)(3)

Monitor CD4 count: At initial antenatal visit (AI) At least every 3 months during pregnancy (BIII), or

every 6 months in women on ART for more than 2-3 years who are adherent, clinically stable, and have sustained viral suppression (CIII)

August 201216 www.aidsetc.org

Page 17: ANTEPARTUM CARE

Maternal and Fetal Monitoring during Pregnancy (4)

Perform genotypic drug resistance testing at baseline if VL >500-1,000 copies/mL, whether they are ARV naive or currently on ART. (AIII) Repeat testing in women who have suboptimal viral

suppression on ART or who have persistent viral rebound to detectable levels after prior viral suppression on an ARV regimen. (AIII)

August 201217 www.aidsetc.org

Page 18: ANTEPARTUM CARE

Maternal and Fetal Monitoring during Pregnancy (5)

Monitor for complications of ART based on what is known about the adverse effects of the drugs in the regimen. (AIII)

Perform 1st-trimester ultrasound to confirm gestational age and to guide timing of scheduled C-section (if needed). (AII)

August 201218 www.aidsetc.org

Page 19: ANTEPARTUM CARE

Maternal and Fetal Monitoring during Pregnancy (6)

Perform amniocentesis, if indicated, only after initiation of ART regimen and, if possible, when VL is undetectable. (BIII) No perinatal transmission after amniocentesis have

been reported in women on effective ART. Small risk cannot be ruled out.

In women with detectable VL in whom amniocentesis is deemed necessary, consultation with an expert should be considered.

August 201219 www.aidsetc.org

Page 20: ANTEPARTUM CARE

Failure of Viral Suppression (1)

Use a 3-pronged approach for management of suboptimal suppression of VL. Assess for resistant virus (AII) Assess adherence (AII) Consult an expert for consideration of modifying the

ARV regimen (AIII)

Treatment modification has been independently associated with HIV RNA >400 copies/mL during late pregnancy.

August 201220 www.aidsetc.org

Page 21: ANTEPARTUM CARE

Failure of Viral Suppression (2)

Efficacy and safety of adding RAL to an ART regimen during late pregnancy in women with high VL or multiple drug-resistance mutations has not been evaluated and is not recommended. The addition of a single drug to a failing regimen may

further increase risk of resistance and loss of future effectiveness of RAL.

Cesarean delivery is recommended when RNA is >1,000 copies/mL near the time of delivery. (AII)

August 201221 www.aidsetc.org

Page 22: ANTEPARTUM CARE

Resistance Testing during Pregnancy (1)

Drug resistance: Is one of the major factors leading to treatment failure May limit future maternal treatment options and

decrease effectiveness of ARV prophylaxis during current and future pregnancies

Increased risk of resistance During pregnancy with:

Nausea and vomiting PK changes

Postpartum After simultaneous discontinuation of drugs with different

half-lives

August 201222 www.aidsetc.org

Page 23: ANTEPARTUM CARE

Resistance Testing during Pregnancy (2)

Recommendations:Perform drug resistance studies before starting or modifying ART for all pregnant women with detectable VL prior to initiation of ART (AIII) and for those with detectable VL while on ART or suboptimal suppression after starting ART. (AII)

Start empiric ART for women who present during late pregnancy; adjust regimen as needed when results are available. (BIII)

August 201223 www.aidsetc.org

Page 24: ANTEPARTUM CARE

Resistance Testing during Pregnancy (3)

Give all HIV-infected pregnant women maximally suppressive ART. (AII)

Provide counseling and support for adherence. (AII)

August 201224 www.aidsetc.org

Page 25: ANTEPARTUM CARE

Stopping ARVs during Pregnancy (1)

Women who are on ART and present in the 1st trimester should continue therapy. (AII) Although EFV should be avoided during the first

trimester when possible, therapy should NOT be interrupted in women taking the drug who present in the 1st trimester.

August 201225 www.aidsetc.org

Page 26: ANTEPARTUM CARE

Stopping ARVs during Pregnancy (2)

Discontinuation of ART during pregnancy may be indicated in some situations.

If ART is stopped acutely for severe or life-threatening toxicity, severe hyperemesis, or other acute illness that precludes oral intake, all ARV drugs should be stopped and reinitiated at the same time. (AIII)

August 201226 www.aidsetc.org

Page 27: ANTEPARTUM CARE

Stopping ARVs during Pregnancy (3)

If an NNRTI-based regimen is being stopped electively, consider either: Stopping NNRTI first and continue other ARVs for a

period; or Switching from an NNRTI to a PI before interruption;

continue PI-based regimen for a period. Optimum period of time is unknown. At least 7 days is

recommended. (CIII) For EFV-based regimens, some experts recommend up

to 30 days. (CIII) If NVP is restarted after >2 weeks, restart with the 2-

week half-dose escalation period. (AII)

August 201227 www.aidsetc.org